Tesamorelin is a GHRH analog. It is filed in this library under digestive & weight, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Tesamorelin has an FDA-approved product on the U.S. market, marketed as Egrifta Sv under application BLA022505.
The current label is held by Theratechnologies Inc.
From the FDA label
is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Limitations of Use: Long-term cardiovascular safety of EGRIFTA SV has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue. EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect. There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA SV. EGRIFTA SV is a growth hormone-releasing factor (GHRF) analog indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Limitations of use: Long-term cardiovascular safety of EGRIFTA SV has not been established. Not indicated for weight loss management.Quoted from the FDA-approved prescribing information
The evidence
7 sources on Tesamorelin published between 2007 and 2019, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.
Nearby
Markers on this pathway
Tesamorelin's FDA-approved label indicates it for acromegaly or for a growth disorder, which are assessed on this axis. These are the markers clinicians use when assessing the growth hormone axis. They are listed here so you can read about them, not as a statement that Tesamorelin changes any of them.
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Tesamorelin. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides